Oct 27 Bristol-Myers Squibb Co reported better than expected quarterly earnings, fueled by surging sales of its recently approved Opdivo immuno-oncology drug, hepatitis C treatments and its Eliquis blood clot preventer.
The company said it earned $706 million, or 42 cents per share, in the third quarter. That compared with $721 million, or 43 cents per share, in the year-earlier period.
21:31 Time Warner jumps after hours on report it could sell for $110 per share to AT&T
12:55 McDonald's shares pop as investors cheer third-quarter beat
11:10 Merged BAT-Reynolds could be loaded with up to $55 billion of debt, analysts say
23:06 AT&T discussed takeover in meetings with Time Warner: Bloomberg